Patterns of Medication Initiation in Newly Diagnosed Diabetes Mellitus: Quality and Cost Implications



      Six oral medication classes have been approved by the Food and Drug Administration for the treatment of type 2 diabetes. Although all of these agents effectively lower blood glucose, the evidence supporting their impact on other clinical events is variable. There also are substantial cost differences between agents. We aimed to evaluate temporal trends in the use of specific drugs for the initial management of type 2 diabetes and to estimate the economic consequences of non-recommended care.


      We studied a cohort of 254,973 patients, aged 18 to 100 years, who were newly initiated on oral hypoglycemic monotherapy between January 1, 2006, and December 31, 2008, by using prescription claims data from a large pharmacy benefit manager. Linear regression models were used to assess whether medication initiation patterns changed over time. Multivariate logistic regression models were constructed to identify independent predictors of receiving initial therapy with metformin. We then measured the economic consequences of prescribing patterns by drug class for both patients and the insurer.


      Over the course of the study period, the proportion of patients initially treated with metformin increased from 51% to 65%, whereas those receiving sulfonylureas decreased from 26% to 18% (P<.001 for both). There was a significant decline in the use of thiazolidinediones (20.1%-8.3%, P<.001) and an increase in prescriptions for dipeptidyl peptidase-4 inhibitors (0.4%-7.3%, P<.001). Younger patients, women, and patients receiving drug benefits through Medicare were least likely to initiate treatment with metformin. Combined patient and insurer spending for patients who were initiated on alpha-glucosidase inhibitors, thiazolidinediones, meglitinides, or dipeptidyl peptidase-4 inhibitors was $677 over a 6-month period compared with $116 and $118 for patients initiated on metformin or a sulfonylurea, respectively, a cost difference of approximately $1120 annually per patient.


      Approximately 35% of patients initiating an oral hypoglycemic drug did not receive recommended initial therapy with metformin. These practice patterns also have substantial implications for health care spending.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • World Health Organization
        (Accessed October 7, 2010)
        • Centers for Disease Control Diabetes Statistics 2007
        (Accessed October 7, 2010)
        • Boyle J.P.
        • Honeycutt A.A.
        • Narayan K.M.
        • et al.
        Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S..
        Diabetes Care. 2001; 24: 1936-1940
      1. Economic costs of diabetes in the U.S. In 2007.
        Diabetes Care. 2008; 31: 596-615
      2. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. 2007;147:386-399. Epub 2007 Jul 16.

      3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
        Lancet. 1998; 352: 837-853
        • Nissen S.E.
        • Wolski K.
        Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
        N Engl J Med. 2007; 356: 2457-2471
        • Graham D.J.
        • Ouellet-Hellstrom R.
        • MaCurdy T.E.
        • et al.
        Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.
        JAMA. 2010; 304 (Epub 2010 Jun 28): 411-418
      4. Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus' trial (SAVOR-TIMI 53) (NCT01107886).
        (Accessed September 21, 2011)
      5. A Randomized Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Mono- or Dual Combination Oral Antihyperglycemic Therapy (TECOS) (NCT00790205).
        (Accessed September 21, 2011)
        • Nathan D.M.
        • Buse J.B.
        • Davidson M.B.
        • et al.
        Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.
        Diabetes Care. 2006; 29: 1963-1972
        • Nathan D.M.
        • Buse J.B.
        • Davidson M.B.
        • et al.
        Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.
        Diabetes Care. 2009; 32: 193-203
        • Shrank W.H.
        • Cox E.R.
        • Fischer M.A.
        • Mehta J.
        • Choudhry N.K.
        Patients' perceptions of generic medications.
        Health Aff (Millwood). 2009; 28: 546-556
        • Woodcock J.
        • Sharfstein J.M.
        • Hamburg M.
        Regulatory action on rosiglitazone by the U.S. Food and Drug Administration.
        N Engl J Med. 2010; 363: 1489-1491
        • Choudhry N.
        • Cox E.
        • Fischer M.A.
        • Mehta J.
        • Shrank W.H.
        Setting prices for generic medications: a survey of patient perceptions.
        Am J Pharm Benefits. 2010; 2: 6
        • Schramm T.K.
        • Gislason G.H.
        • Vaag A.
        • et al.
        Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.
        Eur Heart J. 2011; 32 (Epub 2011 Apr 6): 1900-1908
        • Choudhry N.K.
        • Shrank W.H.
        Four-dollar generics—increased accessibility, impaired quality assurance.
        N Engl J Med. 2010; 363: 1885-1887

      Linked Article

      • Physicians' Prescribing Patterns for Patients with Diabetes Are Changing for the Better
        The American Journal of MedicineVol. 125Issue 11
        • Preview
          Desai et al1 reported that 35% of patients with type 2 diabetes initiating oral hypoglycemic therapy did not receive the initial therapy with metformin recommended by the 2009 algorithm of the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD). The 2009 ADA/EASD Algorithm2 has recently been superseded by a new Position Statement from those 2 organizations.3 The 2012 statement also recommends metformin as the drug of first choice when initiating monotherapy and as part of dual or triple therapy.
        • Full-Text
        • PDF